EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPTBiotechnology
+$0.26 today
- Market cap
- $250.69M
- Beta
- 1.75
- P/E (TTM)
- -4.2
- EPS (TTM)
- -$3.16
Volume 2.75M
Average 0.95M
EYPT Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
EyePoint Pharmaceuticals, Inc.NASDAQ: EYPT
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $72.15M rose 23.2% year over year, behind the +45.4% change in trailing-twelve-month research & development. Sequentially, it rose 21.8% from the prior quarter. Over 3 fiscal years it compounded at +64.5% a year.
Context
- Research & development amounted to 704.6% of revenue in FY2025, up 397.4 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +23.2% toward the trailing-twelve-month pace of +45.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 221.04M USD
- Year-over-year change
- +66.3%
- 4-year CAGR
- +66.9%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 221.04M | +66.3% |
| FY2024 | 2024-12-31 | 132.93M | +105.6% |
| FY2023 | 2023-12-31 | 64.66M | +30.3% |
| FY2022 | 2022-12-31 | 49.64M | +74.2% |
| FY2021 | 2021-12-31 | 28.5M | — |
Research & Development vs competitors
How EYPT compares with its peers on the latest reported figures
- EYPT's LTM Mar 2026 research & development of $234.61M is the 3rd highest of the 11 companies compared; the peer median is $142.57M.
- Its year-over-year change of +45.4% is the 2nd highest of 11, against a peer median of +12.3%.
- Research & development amounts to 3080.9% of revenue for EYPT, versus a peer median of 363.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $331.95M | +10.2% | +18.6% | 47.3% | |
| LTM Mar 2026 | $260.36M | +37.3% | +39.3% | 363.4% | |
| LTM Mar 2026 | $234.61M | +45.4% | +64.5% | 3080.9% | |
| LTM Sep 2026 | $208.43M | +23.6% | -12.0% | — | |
| LTM Mar 2026 | $154.18M | -2.5% | +22.8% | 3822.0% | |
| LTM Sep 2026 | $152.48M | +14.3% | +7.7% | — | |
SEPNSepterna, Inc. | LTM Sep 2026 | $132.66M | +56.0% | — | 137.8% |
| LTM Mar 2026 | $120.7M | -5.5% | +11.6% | 13577.3% | |
BCAXBicara Therapeutics Inc. Common Stock | LTM Mar 2026 | $111.11M | +29.3% | +58.7% | — |
| LTM Mar 2026 | $85.64M | +6.5% | +42.9% | — | |
| LTM Mar 2026 | $59.77M | +0.0% | +23.7% | — | |
| Peer median (excluding EYPT) | $142.57M | +12.3% | +22.8% | 363.4% | |
Competitors are the stored peer set for EYPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 36.94M | 41.4M | 46.02M | 43.27M | 31.37M |
| Cost of Revenue | 8.18M | 8.33M | 4.63M | 3.71M | 2.07M |
| Gross Profit | 28.76M | 33.08M | 41.39M | 39.56M | 29.31M |
| Gross Margin | 77.9% | 79.9% | 89.9% | 91.4% | 93.4% |
| Research & Development | 28.5M | 49.64M | 64.66M | 132.93M | 221.04M |
| Selling, General & Admin | 53.08M | 60.32M | 51.79M | 52.49M | 51.7M |
| Operating Expenses | 84.04M | 132.72M | 116.45M | 185.42M | 272.74M |
| Depreciation & Amortization | 2.77M | 2.45M | 464K | 1.54M | 2.31M |
| EBITDA | (50.15M) | (96.62M) | (69M) | (129.23M) | (229.34M) |
| EBITDA Margin | -135.8% | -233.4% | -149.9% | -298.6% | -731.1% |
| Operating Income | (55.28M) | (99.64M) | (75.07M) | (145.85M) | (243.43M) |
| Operating Margin | -149.6% | -240.6% | -163.1% | -337.1% | -776.0% |
| Interest Income | 292K | 2.13M | 6.95M | 15.09M | 11.75M |
| Interest Expense | 5.5M | 3.19M | 1.25M | 14K | (33K) |
| Other Income / Expenses | (3.14M) | (2.62M) | 4.36M | 15.07M | 11.75M |
| Income Before Tax | (58.42M) | (102.25M) | (70.71M) | (130.78M) | (231.68M) |
| Pre-Tax Margin | -158.1% | -247.0% | -153.7% | -302.2% | -738.5% |
| Income Tax Expense | 0 | 0 | 83K | 90K | 279K |
| Net Income | (58.42M) | (102.25M) | (70.8M) | (130.87M) | (231.96M) |
| Net Margin | -158.1% | -247.0% | -153.8% | -302.4% | -739.4% |
| EPS (Basic) | (2.03) | (2.74) | (1.82) | (2.32) | (3.17) |
| EPS (Diluted) | (2.03) | (2.74) | (1.82) | (2.32) | (3.17) |
| Weighted Avg Shares | 28.76M | 37.32M | 38.9M | 56.3M | 73.25M |
| Weighted Avg Shares (Diluted) | 28.76M | 37.32M | 38.9M | 56.3M | 73.25M |
EyePoint Pharmaceuticals, Inc.
NASDAQ:EYPT
Intrinsic Alpha fair value
Locked
Current Price
$2.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.